Postmarketing studies for approved human drug and licensed biological products; status reports.  Food and Drug Administration, HHS.  Final rule.
The Food and Drug Administration (FDA) is revising the requirements for annual postmarketing status reports for approved human drug and biological products, and is requiring applicants to submit annual status reports for certain postmarketing studies of licensed biological products.  This rule describes the types of postmarketing studies covered by these status reports, the information to be included in the reports, and the type of information that FDA would consider appropriate for public disclosure.  This action will implement the Food and Drug Administration Modernization Act of 1997 (FDAMA).
D017277:Drug Approval / Q000331:legislation & jurisprudence; D006801:Humans; D011358:Product Surveillance, Postmarketing / Q000592:standards; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence